Arrowhead Pharmaceuticals, Inc. (ARWR) bonds
ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$42.99−1.22 (-2.76%)
Close on Nov 17, 2026Market cap $6.07BP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Arrowhead Pharmaceuticals reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Notes and loans outstanding
As tagged in Arrowhead Pharmaceuticals's 10-Q for the period ended Jun 30, 2026
| Issue | Coupon | Amount issued | Carrying value |
|---|---|---|---|
| Convertible Notes Convertible at $87 a share | 0.00% | $700.00M | $700.00M |
| Financing Agreement | 15.00% | – | – |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size | Available | Drawn |
|---|---|---|---|
| Financing Agreement | $500.00M | $100.00M | $400.00M |
| Financing Agreement, Initial Term Loan | – | – | $400.00M |
| Financing Agreement, Initial Term Loan Interest | – | – | $66.94M |
| Revolving Credit Facility | CN¥72.90M | – | – |
| Secured Debt | – | – | $345.63M |
See a number that looks wrong?